Suven Life Sciences received a rectification order from the Income Tax Department, Kondapur, Hyderabad, for assessment year 2020-21. The order, communicated via email on May 28, 2026, disallows the weighted deduction claimed under Section 35(2AB) of the Income Tax Act, 1961, concerning expenditure incurred on Research & Development activities. The disallowance was attributed to the absence of approval from the Department of Scientific and Industrial Research (DSIR) in Form No. 3CL in the order passed under section 143(3) of the Act.

The company stated that it had previously submitted a detailed reply addressing both legal aspects and the merits of the case to contest the notice. However, the Assessing Officer passed the rectification order under Section 154 of the Act without considering the company's contentions. Suven Life Sciences has indicated that it intends to prefer an appeal to the appellate authority against this order.

Regulatory Disclosure Details

The disclosure was made to the exchanges pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The following table summarizes the key details of the regulatory action:

Suven Life Sciences affirmed that it does not foresee any material impact of this order on its financials, operations, or other activities. The company is proceeding with the appeal process to challenge the disallowance.

Suven Life Sciences announced its audited financial results for the quarter and year ended March 31, 2026, at its Board of Directors meeting held on May 13, 2026, in Hyderabad. Pursuant to Regulation 47 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements regarding these audited financial results on May 14, 2026, in Andhra Prabha (Telugu) and Business Standard. The advertisements are also hosted on the company's website at www.suven.com/newspaperads.aspx . The results were reviewed by the Audit Committee and approved by the Board under Regulation 33 of the SEBI (LODR) Regulations, 2015.

Consolidated Financial Performance

The company reported a consolidated net loss of ₹2,763.44 million for the financial year, compared to a net loss of ₹1,607.45 million in the previous year. Revenue from operations for the year increased to ₹210.45 million from ₹175.53 million in FY25. For the quarter ended March 31, 2026, the company posted a net loss of ₹455.96 million on revenue of ₹82.98 million. The company's R&D and operational expenses for the year stood at ₹2,916.18 million, reflecting its continued investment in drug discovery and development. The following table summarises the key consolidated financial metrics:

Standalone Financial Performance

On a standalone basis, Suven Life Sciences reported revenue from operations of Rs. 711.47 lakhs for the year ended March 31, 2026, compared to Rs. 665.58 lakhs in the previous year. The standalone net loss for the year stood at Rs. 5,486.28 lakhs, against Rs. 4,707.98 lakhs in FY25. Total standalone expenses for the year were Rs. 7,588.80 lakhs, with R&D expenses at Rs. 2,797.24 lakhs and employee benefits expense at Rs. 2,414.94 lakhs. Standalone basic and diluted EPS for the year was Rs. (2.41), compared to Rs. (2.16) in FY25. The newspaper advertisement published in Business Standard also disclosed the following summary of standalone and consolidated financial results:

Preferential Issue and Capital Activity

The Board of Directors approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees, with each warrant convertible into one equity share of face value ₹1/- at an exercise price of ₹134/- per share, within 18 months from the date of allotment. Out of the total issue proceeds of Rs. 85,764 lakhs, Rs. 76,432.53 lakhs has been received, while Rs. 9,331 lakhs is yet to be received from warrant holders. During the period from July 2025 to March 2026, the company allotted 4,54,32,866 equity shares on conversion of an equivalent number of fully paid warrants to six allottees, upon receipt of 100% of the warrant consideration amounting to Rs. 60,880.04 lakhs.

Corporate Governance and AGM

The Board noted the acceptance of a waiver of fines by BSE, as communicated vide email dated April 23, 2026, in respect of penal actions imposed for non-compliance with Regulation 19 of the SEBI (LODR) Regulations, 2015 pertaining to a prior period. The outcome of a similar waiver application from NSE is still pending. The Board advised management to exercise greater diligence in ensuring strict compliance with regulations and also recommended seeking external professional advice in cases of ambiguity or uncertainty in the interpretation of applicable regulations. Additionally, the company scheduled its 37th Annual General Meeting for August 25, 2026, via video conferencing.

Clinical Pipeline Update

Suven provided updates on its clinical-stage assets spanning multiple CNS disorders. The company also granted 7 patents during the period covering countries ARIPO, EPO, Japan, and Mexico. The following table summarises the status of each pipeline asset: